Boston Scientific Co. (NYSE: BSX) Given Average Recommendation of “Buy” by Analysts


Shares of Boston Scientific Co. (NYSE: BSX – Get Rating) have received a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $ 49.17.

BSX has been the subject of several research reports. Raymond James reduced their price target on shares of Boston Scientific from $ 51.00 to $ 49.00 and set a “strong-buy” rating for the company in a research report on Thursday, February 3rd. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Thursday, April 21st. TheStreet downgraded shares of Boston Scientific from a “b” rating to a “c +” rating in a research report on Tuesday, March 8th. Bank of America assumed coverage on shares of Boston Scientific in a report on Tuesday, March 1st. They set a “buy” rating on the stock. Finally, Truist Financial assumed coverage on shares of Boston Scientific in a report on Wednesday, April 13th. They set a “buy” rating and a $ 52.00 objective price on the stock.

In other news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $ 44.47, for a total transaction of $ 333,525.00. Following the sale, the executive vice president now directly owns 147,413 shares in the company, valued at approximately $ 6,555,456.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey B. Mirviss sold 10,989 shares of the business’s stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $ 45.50, for a total value of $ 499,999.50. Following the completion of the sale, the executive vice president now owns 119,961 shares in the company, valued at $ 5,458,225.50. The disclosure for this sale can be found here. Insiders have sold a total of 108,576 shares of company stock worth $ 4,725,374 over the last quarter. Company insiders own 0.71% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. UMB Bank NA MO purchased a new stake in shares of Boston Scientific during the 4th quarter valued at approximately $ 25,000. CVA Family Office LLC bought a new stake in Boston Scientific during the 4th quarter valued at $ 28,000. Zullo Investment Group Inc. purchased a new stake in shares of Boston Scientific during the fourth quarter worth $ 28,000. Concorde Financial Corp. bought a new position in shares of Boston Scientific in the fourth quarter worth $ 34,000. Finally, Quent Capital LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $ 35,000. 90.48% of the stock is currently owned by institutional investors.

NYSE: BSX opened at $ 39.66 on Friday. The company has a fifty day moving average of $ 43.12 and a 200-day moving average of $ 42.67. Boston Scientific has a twelve month low of $ 37.96 and a twelve month high of $ 47.49. The company has a quick ratio of 1.10, a current ratio of 1.48 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $ 56.70 billion, a P / E ratio of 74.83, a P / E / G ratio of 2.22 and a beta of 0.81.

Boston Scientific (NYSE: BSX – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical equipment provider reported $ 0.39 earnings per share (EPS) for the quarter, meeting the consensus estimate of $ 0.39. Boston Scientific had a net margin of 6.65% and a return on equity of 14.60%. The business had revenue of $ 3.03 billion during the quarter, compared to the consensus estimate of $ 2.95 billion. During the same quarter last year, the firm posted $ 0.37 EPS. Boston Scientific’s revenue was up 10.0% compared to the same quarter last year. On average, analysts anticipate that Boston Scientific will post 1.76 EPS for the current fiscal year.

Boston Scientific Company Profile (Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

See Also

Analyst Recommendations for Boston Scientific (NYSE: BSX)



Receive News & Ratings for the Boston Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Boston Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.

Back to top button